Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Rhythm Pharmaceuticals to host conference call » 12:35
01/20/21
01/20
12:35
01/20/21
12:35
RYTM

Rhythm Pharmaceuticals

$34.90 /

+0.9 (+2.65%)

Conference call to…

Conference call to provide an update on Phase 2 Basket Study and genetic sequencing efforts will be held on January 26 at 8 am. Webcast Link

ShowHide Related Items >><<
RYTM Rhythm Pharmaceuticals
$34.90 /

+0.9 (+2.65%)

RYTM Rhythm Pharmaceuticals
$34.90 /

+0.9 (+2.65%)

01/05/21 Stifel
Rhythm Pharmaceuticals named a top pick, price target boosted to $36 at Stifel
11/30/20 Goldman Sachs
Goldman keeps Sell rating on Rhythm Pharmaceuticals after Imcivree approval
11/30/20 Ladenburg
Rhythm likely to sell Pediatric Review Voucher for $100M, says Ladenburg
11/30/20 BofA
Rhythm Pharmaceuticals downgraded to Neutral from Buy at BofA
RYTM Rhythm Pharmaceuticals
$34.90 /

+0.9 (+2.65%)

RYTM Rhythm Pharmaceuticals
$34.90 /

+0.9 (+2.65%)

Tuesday
Hot Stocks
Rhythm Pharmaceuticals to provide update on Phase 2 Basket study » 08:27
01/19/21
01/19
08:27
01/19/21
08:27
RYTM

Rhythm Pharmaceuticals

$34.22 /

+0.25 (+0.74%)

Rhythm Pharmaceuticals…

Rhythm Pharmaceuticals announced that it plans to host a virtual event on Tuesday, January 26, 2021 from 8 to 10 a.m. ET to provide an update on its ongoing exploratory Phase 2 Basket Study and genetic sequencing efforts. At the event, Rhythm management plans to report data for setmelanotide in individuals living with heterozygous obesity due to genetic variants in one of two alleles of the POMC, PCSK1 or LEPR gene, as well as SRC1 and SH2B1 deficiency obesities, and plans to provide an update on data from the Company's sequencing efforts, which now comprises samples from approximately 37,500 individuals with severe obesity.

ShowHide Related Items >><<
RYTM Rhythm Pharmaceuticals
$34.22 /

+0.25 (+0.74%)

RYTM Rhythm Pharmaceuticals
$34.22 /

+0.25 (+0.74%)

01/05/21 Stifel
Rhythm Pharmaceuticals named a top pick, price target boosted to $36 at Stifel
11/30/20 Goldman Sachs
Goldman keeps Sell rating on Rhythm Pharmaceuticals after Imcivree approval
11/30/20 Ladenburg
Rhythm likely to sell Pediatric Review Voucher for $100M, says Ladenburg
11/30/20 BofA
Rhythm Pharmaceuticals downgraded to Neutral from Buy at BofA
RYTM Rhythm Pharmaceuticals
$34.22 /

+0.25 (+0.74%)

RYTM Rhythm Pharmaceuticals
$34.22 /

+0.25 (+0.74%)

Over a week ago
Recommendations
Rhythm Pharmaceuticals named a top pick, price target boosted to $36 at Stifel » 09:14
01/05/21
01/05
09:14
01/05/21
09:14
RYTM

Rhythm Pharmaceuticals

$30.41 /

+0.67 (+2.25%)

Stifel analyst Derek…

Stifel analyst Derek Archila raised the firm's price target on Rhythm Pharmaceuticals to $36 from $35 and keeps a Buy rating on the shares while naming it one of his two top picks for 2021 in the small to mid cap biotech space. He thinks results from the ongoing Phase 2 basket trial and an upcoming update on the potential for a Phase 3 registrational basket trial for IMCIVREE could "meaningfully expedite" expanding IMCIVREE's total addressable market "many times over," Archila tells investors.

ShowHide Related Items >><<
RYTM Rhythm Pharmaceuticals
$30.41 /

+0.67 (+2.25%)

RYTM Rhythm Pharmaceuticals
$30.41 /

+0.67 (+2.25%)

11/30/20 Goldman Sachs
Goldman keeps Sell rating on Rhythm Pharmaceuticals after Imcivree approval
11/30/20 Ladenburg
Rhythm likely to sell Pediatric Review Voucher for $100M, says Ladenburg
11/30/20 BofA
Rhythm Pharmaceuticals downgraded to Neutral from Buy at BofA
RYTM Rhythm Pharmaceuticals
$30.41 /

+0.67 (+2.25%)

RYTM Rhythm Pharmaceuticals
$30.41 /

+0.67 (+2.25%)

Hot Stocks
Rhythm Pharmaceuticals announces sale of Priority Review Voucher for $100M » 08:19
01/05/21
01/05
08:19
01/05/21
08:19
RYTM

Rhythm Pharmaceuticals

$30.41 /

+0.67 (+2.25%)

Rhythm Pharmaceuticals…

Rhythm Pharmaceuticals announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $100M. The PRV was granted to Rhythm by the U.S. Food and Drug Administration with the approval of IMCIVREE for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin, proprotein convertase subtilisin/kexin type 1 or leptin receptor deficiency confirmed by genetic testing. According to the agreement, Rhythm will receive an upfront payment of $100M upon the closing of the transaction, which is subject to customary closing conditions and is expected to occur following expiration of the applicable U.S. antitrust clearance requirements. Jefferies LLC acted as exclusive financial advisor to Rhythm on this transaction. Latham & Watkins LLP acted as legal advisor to Rhythm. The non-dilutive funds expected from this transaction are in addition to the $201.8M in cash, cash equivalents and short-term investments Rhythm reported as of September 30, 2020.

ShowHide Related Items >><<
RYTM Rhythm Pharmaceuticals
$30.41 /

+0.67 (+2.25%)

RYTM Rhythm Pharmaceuticals
$30.41 /

+0.67 (+2.25%)

11/30/20 Goldman Sachs
Goldman keeps Sell rating on Rhythm Pharmaceuticals after Imcivree approval
11/30/20 Ladenburg
Rhythm likely to sell Pediatric Review Voucher for $100M, says Ladenburg
11/30/20 BofA
Rhythm Pharmaceuticals downgraded to Neutral from Buy at BofA
11/27/20 Stifel
Rhythm's Imcivree label 'reads bullish' for possible basket trial, says Stifel
RYTM Rhythm Pharmaceuticals
$30.41 /

+0.67 (+2.25%)

RYTM Rhythm Pharmaceuticals
$30.41 /

+0.67 (+2.25%)

Over a month ago
Hot Stocks
Rhythm says Phase 3 trial of setmelanotide meets primary endpoint » 07:03
12/22/20
12/22
07:03
12/22/20
07:03
RYTM

Rhythm Pharmaceuticals

$29.44 /

+0.62 (+2.15%)

Rhythm Pharmaceuticals…

Rhythm Pharmaceuticals announced positive topline results from a pivotal Phase 3 clinical trial evaluating setmelanotide, the company's melanocortin-4 receptor agonist, for the treatment of insatiable hunger and severe obesity in individuals with Bardet-Biedl syndrome or Alstrom syndrome. The study met its primary and all key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in weight and hunger scores. All primary endpoint responders were patients with BBS. There were three evaluable patients with Alstrom syndrome and none of them met the primary endpoint. Rhythm enrolled 32 individuals with BBS and six individuals with Alstrom syndrome in the pivotal cohort for this Phase 3 trial. The primary analysis was conducted on 31 evaluable participants 12 years old and older. Five study participants were younger than 12 years old at enrollment. The analysis of the primary endpoint shows: 11 of 31 or 34.5 percent1 of participants achieved the primary endpoint of at least 10 percent reduction in body weight from baseline at approximately 52 weeks of therapy; 11 of 28 patients with BBS achieved 10 percent reduction in body weight; 0 of 3 patients with Alstrom syndrome achieved 10 percent reduction in body weight. The analysis of the key secondary endpoints shows: Mean reduction from baseline in body weight was -6.2 percent; Mean reduction from baseline in most hunger rating was -30.8 percent; 60.2 percent of participants achieved at least 25 percent reduction in most hunger scores from baseline at approximately 52 weeks of therapy. Consistent with prior clinical experience, setmelanotide was generally well tolerated: Treatment-emergent adverse events included mild injection site reactions and nausea with infrequent vomiting; There were no serious adverse events related to treatment with setmelanotide; Eight patients discontinued from study drug treatment during the trial, five due to AEs, and three for other reasons. Rhythm plans to complete regulatory submissions to both the U.S. Food and Drug Administration and the European Medicines Association for BBS in the second half of 2021. The company expects to finalize a path forward for Alstrom syndrome upon completing a full analysis of the final data from this trial.

ShowHide Related Items >><<
RYTM Rhythm Pharmaceuticals
$29.44 /

+0.62 (+2.15%)

RYTM Rhythm Pharmaceuticals
$29.44 /

+0.62 (+2.15%)

11/30/20 Goldman Sachs
Goldman keeps Sell rating on Rhythm Pharmaceuticals after Imcivree approval
11/30/20 Ladenburg
Rhythm likely to sell Pediatric Review Voucher for $100M, says Ladenburg
11/30/20 BofA
Rhythm Pharmaceuticals downgraded to Neutral from Buy at BofA
11/27/20 Stifel
Rhythm's Imcivree label 'reads bullish' for possible basket trial, says Stifel
RYTM Rhythm Pharmaceuticals
$29.44 /

+0.62 (+2.15%)

RYTM Rhythm Pharmaceuticals
$29.44 /

+0.62 (+2.15%)

Hot Stocks
Rhythm Pharmaceuticals appoints Camille Bedrosian, Lynn Tetrault to board » 08:19
12/11/20
12/11
08:19
12/11/20
08:19
RYTM

Rhythm Pharmaceuticals

$28.38 /

+0.13 (+0.46%)

, RARE

Ultragenyx

$133.90 /

+4.8 (+3.72%)

, AZN

AstraZeneca

$53.90 /

-0.14 (-0.26%)

Rhythm Pharmaceuticals…

Rhythm Pharmaceuticals (RYTM) announced the appointments of Camille Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors. Bedrosian serves as EVP and CMO at Ultragenyx Pharmaceutical (RARE). Tetrault spent more than 20 years at AstraZeneca (AZN), including seven years as EVP for Human Resources and Corporate Affairs.

ShowHide Related Items >><<
RYTM Rhythm Pharmaceuticals
$28.38 /

+0.13 (+0.46%)

RARE Ultragenyx
$133.90 /

+4.8 (+3.72%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

RYTM Rhythm Pharmaceuticals
$28.38 /

+0.13 (+0.46%)

11/30/20 Goldman Sachs
Goldman keeps Sell rating on Rhythm Pharmaceuticals after Imcivree approval
11/30/20 Ladenburg
Rhythm likely to sell Pediatric Review Voucher for $100M, says Ladenburg
11/30/20 BofA
Rhythm Pharmaceuticals downgraded to Neutral from Buy at BofA
11/27/20 Stifel
Rhythm's Imcivree label 'reads bullish' for possible basket trial, says Stifel
RARE Ultragenyx
$133.90 /

+4.8 (+3.72%)

12/07/20
Fly Intel: Top five analyst downgrades
12/07/20 Wedbush
Ultragenyx downgraded to Neutral from Outperform at Wedbush
11/23/20 Evercore ISI
Ultragenyx resumed with an In Line at Evercore ISI
11/12/20 BofA
Ultragenyx downgraded to Neutral from Buy at BofA
AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

12/07/20
Fly Intel: Top five analyst upgrades
12/07/20 Morgan Stanley
AstraZeneca upgraded to Overweight from Equal Weight at Morgan Stanley
12/01/20 Morgan Stanley
COVID mRNA vaccines seen with vast majority of U.S. market, says Morgan Stanley
11/30/20 UBS
AstraZeneca upgraded to Neutral from Sell at UBS
RYTM Rhythm Pharmaceuticals
$28.38 /

+0.13 (+0.46%)

RARE Ultragenyx
$133.90 /

+4.8 (+3.72%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

  • 29
    Oct
RARE Ultragenyx
$133.90 /

+4.8 (+3.72%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

RYTM Rhythm Pharmaceuticals
$28.38 /

+0.13 (+0.46%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

AZN AstraZeneca
$53.90 /

-0.14 (-0.26%)

Recommendations
Goldman keeps Sell rating on Rhythm Pharmaceuticals after Imcivree approval » 06:53
11/30/20
11/30
06:53
11/30/20
06:53
RYTM

Rhythm Pharmaceuticals

$29.27 /

+5.16 (+21.40%)

Goldman Sachs analyst…

Goldman Sachs analyst Graig Suvannavejh keeps a Sell rating and unchanged $18 price target on Rhythm Pharmaceuticals after FDA approval for Imcivree came on time and per his expectations with a "reasonable" label that seems to him to be consistent with prior approvals requiring genetic testing for confirmation of disease and drug eligibility. The label's warnings could potentially limit market uptake, contends Suvannavejh, who maintains his view that consensus 2021/2022 estimates remain too high for Rhythm.

ShowHide Related Items >><<
RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

11/30/20 Ladenburg
Rhythm likely to sell Pediatric Review Voucher for $100M, says Ladenburg
11/30/20 BofA
Rhythm Pharmaceuticals downgraded to Neutral from Buy at BofA
11/27/20 Stifel
Rhythm's Imcivree label 'reads bullish' for possible basket trial, says Stifel
10/26/20 Stifel
Rhythm Pharmaceuticals price target raised to $36 from $31 at Stifel
RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

Recommendations
Rhythm likely to sell Pediatric Review Voucher for $100M, says Ladenburg » 06:48
11/30/20
11/30
06:48
11/30/20
06:48
RYTM

Rhythm Pharmaceuticals

$29.27 /

+5.16 (+21.40%)

Ladenburg Thalmann…

Ladenburg Thalmann analyst Michael Higgins reiterates a Buy rating on Rhythm Pharmaceuticals with a $43 price target after Imcivree received FDA approval for chronic weight management in adult and pediatric patients six years of age and older with obesity due to proopiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency. Rhythm also received a Pediatric Review Voucher due to the early onset of disease, though the company has not yet indicated whether it will sell or keep the PRV, Higgins tells investors in a research note. The analyst believes the company will sell its PRV for $100M. The PRV and cash should get Rhythm to profitability in 2022, says Higgins.

ShowHide Related Items >><<
RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

11/30/20 BofA
Rhythm Pharmaceuticals downgraded to Neutral from Buy at BofA
11/27/20 Stifel
Rhythm's Imcivree label 'reads bullish' for possible basket trial, says Stifel
10/26/20 Stifel
Rhythm Pharmaceuticals price target raised to $36 from $31 at Stifel
01/08/20 Goldman Sachs
Rhythm Pharmaceuticals initiated with a Sell at Goldman Sachs
RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

Downgrade
Rhythm Pharmaceuticals downgraded to Neutral from Buy at BofA » 06:28
11/30/20
11/30
06:28
11/30/20
06:28
RYTM

Rhythm Pharmaceuticals

$29.27 /

+5.16 (+21.40%)

BofA analyst Tazeen Ahmad…

BofA analyst Tazeen Ahmad downgraded Rhythm Pharmaceuticals to Neutral from Buy with a price target of $33, up from $27. The analyst cites the FDA approval of IMCIVREE announced on Friday for the treatment of obesities due to POMC/PCSK1 and LepR deficiencies, modeling 300 POMC patients and 1,250 LepR patients in the US, but noting that the upside from bigger markets is largely "baked in" to the stock. Ahmad further states that Rhythm will make Imcivree available to patients starting in Q1 of 2021, with aggregate pricing in the range of $290K-$300K per patient annually.

ShowHide Related Items >><<
RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

11/27/20 Stifel
Rhythm's Imcivree label 'reads bullish' for possible basket trial, says Stifel
10/26/20 Stifel
Rhythm Pharmaceuticals price target raised to $36 from $31 at Stifel
01/08/20 Goldman Sachs
Rhythm Pharmaceuticals initiated with a Sell at Goldman Sachs
RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

On The Fly
Fly Intel: Wall Street's top stories for Friday » 13:17
11/27/20
11/27
13:17
11/27/20
13:17
AZN

AstraZeneca

$52.59 /

-0.01 (-0.02%)

, MRNA

Moderna

$126.88 /

+17.7 (+16.21%)

, NVAX

Novavax

$125.68 /

+23.16 (+22.59%)

, SAGE

Sage Therapeutics

$75.59 /

-7.02 (-8.50%)

, BIIB

Biogen

$243.90 /

+1.85 (+0.76%)

, RYTM

Rhythm Pharmaceuticals

$29.27 /

+5.16 (+21.40%)

, MARA

Marathon Patent Group

$4.29 /

-0.805 (-15.80%)

, RIOT

Riot Blockchain

$6.25 /

-0.825 (-11.66%)

Stock futures saw modest…

ShowHide Related Items >><<
SAGE Sage Therapeutics
$75.59 /

-7.02 (-8.50%)

RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

RIOT Riot Blockchain
$6.25 /

-0.825 (-11.66%)

NVAX Novavax
$125.68 /

+23.16 (+22.59%)

MRNA Moderna
$126.88 /

+17.7 (+16.21%)

MARA Marathon Patent Group
$4.29 /

-0.805 (-15.80%)

BIIB Biogen
$243.90 /

+1.85 (+0.76%)

AZN AstraZeneca
$52.59 /

-0.01 (-0.02%)

AZN AstraZeneca
$52.59 /

-0.01 (-0.02%)

11/27/20 Argus
AstraZeneca's COVID vaccine faces high bar for FDA authorization, says Argus
11/27/20 Citi
Citi opens 'positive catalyst watch' on AstraZeneca after vaccine selloff
11/24/20 Piper Sandler
Astra vaccine results 'de-risking' for Altimmune, says Piper Sandler
11/23/20 Morgan Stanley
AstraZeneca price target raised to 9,400 GBp from 9,000 GBp at Morgan Stanley
MRNA Moderna
$126.88 /

+17.7 (+16.21%)

11/25/20 Goldman Sachs
Moderna price target raised to $139 from $107 at Goldman Sachs
11/23/20
Fly Intel: Top five analyst initiations
11/23/20 Wells Fargo
Moderna initiated with an Equal Weight at Wells Fargo
NVAX Novavax
$125.68 /

+23.16 (+22.59%)

11/17/20 H.C. Wainwright
Novavax price target lowered to $207 from $290 at H.C. Wainwright
10/30/20 Cantor Fitzgerald
Cantor says Novavax vaccine could be 'best-in-class,' but not 'first-in-class'
10/22/20 B. Riley Securities
Novavax price target lowered to $223 from $257 at B. Riley Securities
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
SAGE Sage Therapeutics
$75.59 /

-7.02 (-8.50%)

11/27/20 Stifel
Stifel says license deal 'good' for Biogen, takes some upside off table for Sage
11/19/20 Oppenheimer
Sage Therapeutics price target raised to $94 from $65 at Oppenheimer
11/16/20
Fly Intel: Top five analyst downgrades
11/16/20 Morgan Stanley
Morgan Stanley downgrades Sage Therapeutics amid 'reasonable' expectations
BIIB Biogen
$243.90 /

+1.85 (+0.76%)

11/10/20 Truist
Truist raises Biogen price target to $443, views aducanumab approval as 'likely'
11/10/20 DZ Bank
Biogen upgraded to Buy from Hold at DZ Bank
11/09/20 BMO Capital
Biogen price target lowered to $253 from $343 at BMO Capital
RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

11/27/20 Stifel
Rhythm's Imcivree label 'reads bullish' for possible basket trial, says Stifel
10/26/20 Stifel
Rhythm Pharmaceuticals price target raised to $36 from $31 at Stifel
01/08/20 Goldman Sachs
Rhythm Pharmaceuticals initiated with a Sell at Goldman Sachs
MARA Marathon Patent Group
$4.29 /

-0.805 (-15.80%)

11/23/20 H.C. Wainwright
Marathon Patent Group initiated with a Buy at H.C. Wainwright
RIOT Riot Blockchain
$6.25 /

-0.825 (-11.66%)

11/23/20 H.C. Wainwright
Riot Blockchain price target raised to $7.50 from $3.50 at H.C. Wainwright
SAGE Sage Therapeutics
$75.59 /

-7.02 (-8.50%)

RYTM Rhythm Pharmaceuticals
$29.27 /

+5.16 (+21.40%)

NVAX Novavax
$125.68 /

+23.16 (+22.59%)

MRNA Moderna
$126.88 /

+17.7 (+16.21%)

MARA Marathon Patent Group
$4.29 /

-0.805 (-15.80%)

BIIB Biogen
$243.90 /

+1.85 (+0.76%)

AZN AstraZeneca
$52.59 /

-0.01 (-0.02%)

  • 24
    Jul
  • 19
    May
  • 12
    Feb
NVAX Novavax
$125.68 /

+23.16 (+22.59%)

MRNA Moderna
$126.88 /

+17.7 (+16.21%)

BIIB Biogen
$243.90 /

+1.85 (+0.76%)

AZN AstraZeneca
$52.59 /

-0.01 (-0.02%)

SAGE Sage Therapeutics
$75.59 /

-7.02 (-8.50%)

NVAX Novavax
$125.68 /

+23.16 (+22.59%)

MRNA Moderna
$126.88 /

+17.7 (+16.21%)

MARA Marathon Patent Group
$4.29 /

-0.805 (-15.80%)

BIIB Biogen
$243.90 /

+1.85 (+0.76%)

AZN AstraZeneca
$52.59 /

-0.01 (-0.02%)

BIIB Biogen
$243.90 /

+1.85 (+0.76%)

RIOT Riot Blockchain
$6.25 /

-0.825 (-11.66%)

NVAX Novavax
$125.68 /

+23.16 (+22.59%)

MRNA Moderna
$126.88 /

+17.7 (+16.21%)

MARA Marathon Patent Group
$4.29 /

-0.805 (-15.80%)

BIIB Biogen
$243.90 /

+1.85 (+0.76%)

AZN AstraZeneca
$52.59 /

-0.01 (-0.02%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.